Stock SFZN SIEGFRIED HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Siegfried Holding AG

Equities

SFZN

CH0014284498

Market Closed - Swiss Exchange
Other stock markets
 11:30:11 2024-04-19 am EDT 		5-day change 1st Jan Change
889 CHF +1.37% Intraday chart for Siegfried Holding AG -0.89% +3.43%
Apr. 02 Health Care Down on Flight From Risk -- Health Care Roundup DJ
Apr. 02 European Midday Briefing : Stocks Gain as Bonds Track Treasuries Lower DJ

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The firm trades with high earnings multiples: 25.67 times its 2024 earnings per share.
  • The company's enterprise value to sales, at 3.2 times its current sales, is high.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • Revenue estimates are regularly revised downwards for the current and coming years.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SIEGFRIED HOLDING AG Stock Siegfried Holding AG
+3.43% 4.13B
B+
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+24.60% 672B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.08% 550B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.63% 351B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.37% 317B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.38% 292B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+3.26% 211B
B+
NOVARTIS AG Stock Novartis AG
+0.78% 203B
B-
PFIZER, INC. Stock Pfizer, Inc.
-9.69% 144B
C+
AMGEN INC. Stock Amgen Inc.
-6.63% 141B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SFZN Stock
  4. Ratings Siegfried Holding AG